Many mechanisms can contribute to complex diseases such as metabolic diseases; thus, combination therapies may be required to target individual underlying pathological mechanisms. A new study combines glucagon-like peptide-1 (GLP1) and estrogen in a single molecule, allowing selective targeting of this conjugate to cells that express the GLP1 receptor. This strategy improves the metabolic profile of obese mice without the adverse side effects associated with estrogen therapy (pages 1847–1856).
This is a preview of subscription content, log in via an institution to check access.
Debbie Maizels
References
Finan, B. et al. Nat. Med. 18, 1847–1856 (2012).
Dietrich, M.O. & Horvath, T.L. Nat. Rev. Drug Discov. 11, 675–691 (2012).
Zhang, Y. et al. Nature 372, 425–432 (1994).
Halaas, J.L. et al. Science 269, 543–546 (1995).
Dietrich, M.O. & Horvath, T.L. Eur. J. Neurosci. 30, 1688–1696 (2009).
Gao, Q. & Horvath, T.L. Am. J. Physiol. Endocrinol. Metab. 294, E817–E826 (2008).
Kalra, S.P. et al. Endocr. Rev. 20, 68–100 (1999).
Gao, Q. et al. Nat. Med. 13, 89–94 (2007).
Pinto, S. et al. Science 304, 110–115 (2004).
Dietrich, M.O. et al. Nat. Neurosci. 15, 1108–1110 (2012).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Dietrich, M., Horvath, T. A marriage made to last in drug design. Nat Med 18, 1737–1738 (2012). https://doi.org/10.1038/nm.3018
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.3018
- Springer Nature America, Inc.